The Clinical Core of the Pacific Northwest (PNW) Prostate Cancer SPORE will support multiple areas relevant to clinical research, including independent clinical research trials spawning from the Major Projects, biospecimen acquisition, a repository for clinical data, and advocacy activities. Specifically, the 4 major aims are:
Specific Aim 1 : To design, execute, accrue to, and othen/vise facilitate the conduct and timely completion of clinical trials relevant to the Major SPORE projects and cores. Clinical investigators from the University of Washington (UW), the University of British Columbia (UBC), and Oregon Health and Science University (OHSU) will participate in this aspect of the core. New clinical trials are planned specific to Projects 2, 3, 4, and 5. There is a renewed effort to improve minority awareness and accrual to these clinical trials.
Specific Aim 2. To design, direct, and assist in patient recruitment for biospecimen acquisition. Specifically, this will support the logistical aspects of consenting patients and actual acquisition of the biospecimens, including emphasis on patient accrual to the rapid tumor autopsy program.
Specific Aim 3. To continue to direct, support, and enhance CAISIS, our repository of clinical and patient-reported data to support clinical and translational prostate cancer research across the consortium. Key initiatives include Improving the efficiency of data collection, the quality and completeness of the data, and the ability to share data with other investigators and other SPOREs in prostate cancer. We will ensure access to CAISIS data for research across PNW SPORE sites.
Specific Aim 4. To ensure that SPORE Major and Developmental Projects maintain a patient-centered focus, we will support and engage the SPORE Advocacy Committee in the activities of the SPORE. The Advocacy Committee will aid in increasing dissemination of information in regards to clinical trials to prostate cancer support groups and minority patient populations. Advocacy Committee members will set research priority areas that influence selection of funded Developmental Projects.
The Clinical Core is essential to conducting translational clinical research and accomplishing SPORE project aims. In addition, our data repository, CAISIS, will provide ongoing outcomes data that annotate specimens in the Biospecimen Core. These specimens, although useful in and of themselves, have increased value when there is detailed information about prior therapies, patterns of disease, and outcomes.
|Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19|
|Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651|
|Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188|
|Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362|
|Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730|
|Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735|
|Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501|
|Inoue, Lurdes Y T; Lin, Daniel W; Newcomb, Lisa F et al. (2018) Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 168:1-9|
|Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127|
|Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:|
Showing the most recent 10 out of 400 publications